VHL and renal cell carcinoma: Inactivating mutations in VHL are common in ccRCC, and systemic therapy using TKIs has become the standard of care.[25] However, drug resistance remains a major obstacle that limits the long‐term survival benefits of patients with RCC.[26] Hence, exploring the mechanism of TKI resistance is required in order to identify novel targetable candidates.